20.500.12556/DiRROS-29837 Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients Despite progress in treatment, elevated levels of low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) (Lp(a)), represent a significant part of the residual risk. Both are associated with inflammation and the coagulation fibrinolytic system. The purpose of our research was to evaluate the effect of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) on lipid parameters and indicators of inflammation, coagulation and fibrinolysis. We included 100 post myocardial infarction (MI) patients with insufficiently controlled LDL-C values despite the maximum dose of statin, and highly elevated Lp(a). Patients received alirocumab or evolocumab (150 mg sc or 140 mg sc every two weeks, respectively), or placebo for 6 months. In patients receiving PCSK9i, a significant decrease in total cholesterol (TC), LDL-C, triglycerides (TG) and Lp(a), and an increase in high density lipoprotein cholesterol (p < 0.001 for all) was found. Before treatment, the concentrations of TC, LDL-C and TG correlated with the concentrations of thrombin activatable fibrinolysis inhibitor (r = 0.41, p < 0.001; r = 0.353, p < 0.001; r = 0.311, p = 0.003, respectively), and plasminogen activator inhibitor-1 (r = 0.302, p = 0.007; r = 0.218, p = 0.049; r = 0.278; p = 0.013, respectively). The concentrations of TC and LDL-C correlated with overall fibrinolytic potential (r = −0.220, p = 0.034; r = −0.207, p = 0.047, respectively). The concentration of TG was related to the concentration of interleukin 6 (r = 0.290, p = 0.004) and interleukin 8 (r = 0.332, p = 0.001). No correlations between Lp(a) and inflammatory or hemostatic variables were found. No associations were found after treatment. Our results show that inflammatory cytokines and fibrinolytic parameters are related to LDL-C and not Lp(a) in post-MI patients before and with neither of them following PCSK9i treatment. inflammation hemostasis PCSK9 inhibitors LDL cholesterol lipoprotein (a) vnetje hemostaza inhibitorji PCSK9 LDL holesterol lipoprotein (a) true false true Angleški jezik Slovenski jezik Neznano 2026-06-08 11:35:05 2026-06-08 11:35:06 2026-06-09 03:49:20 0000-00-00 00:00:00 2024 0 0 str. 1-8 iss. [article no.] 176232 Vol. 963 Jan. 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-002 0014-2999 10.1016/j.ejphar.2023.176232 179035139 RAZ_Rehberger_Likozar_Andreja_2024.pdf RAZ_Rehberger_Likozar_Andreja_2024.pdf 1 9804FC28ED4DCA5D32373D31BA05FBB9 ff5d9ffc9edabca09c05326bb17bfa921b46d8f678431b011685a0a2941e9740 7c44038d-631d-11f1-9215-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=44878 https://www.sciencedirect.com/science/article/pii/S001429992300746X?via%3Dihub 1 5689c9b5-631d-11f1-9215-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=44877 Univerzitetni klinični center Ljubljana 0 0 0